Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.
Ian Davis takes us through the potentially practice-changing results of the phase III ENZAMET trial evaluating the addition of enzalutamide to standard of care in men with castration-sensitive prostate cancer (3:04).
The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.
The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.
Anders Bjartell outlines the main results of the placebo-controlled TITAN trial of apalutamide in men with castration-sensitive prostate cancer receiving androgen deprivation therapy (2:19).
Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.